#BEGIN_DRUGCARD DB00390

# AHFS_Codes:
24:04.08
80:04.00

# ATC_Codes:
C01AA02
C01AA05
C01AA08
V03AB24

# Absorption:
Absorption of digoxin from the elixir pediatric formulation has been demonstrated to be 70% to 85% complete (90% to 100% from the capsules, and 60% to 80% for tablets).

# Biotransformation:
Hepatic (but not dependent upon the cytochrome P-450 system). The end metabolites, which include 3 b-digoxigenin, 3-keto-digoxigenin, and their glucuronide and sulfate conjugates, are polar in nature and are postulated to be formed via hydrolysis, oxidation, and conjugation.

# Brand_Mixtures:
Not Available

# Brand_Names:
Cardoxin
Cogoxin
Cordioxil
Davoxin
Digacin
Digitekt
Digoxin Pediatric
Dilanacin
Dixina
Dokim
Dynamos
Eudigox
Homolle's Digitalin
Lanacordin
Lanacrist
Lanicor
Lanoxicaps
Lanoxin
Lenoxicaps
Lenoxin
Longdigox
Neo-Lanicor
Neodioxanin
Rougoxin
SK-Digoxin
Stillacor
Vanoxin

# CAS_Registry_Number:
20830-75-5

# ChEBI_ID:
4551

# Chemical_Formula:
C41H64O14

# Chemical_IUPAC_Name:
4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]-2,5-dihydrofuran-2-one

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2242323

# Description:
A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone digoxigenin. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)

# Dosage_Forms:
Liquid	Intravenous
Powder, for solution	Intravenous
Solution	Oral
Tablet	Oral

# Drug_Category:
Anti-Arrhythmia Agents
Antiarrhythmic Agents
Cardiotonic Agents
Enzyme Inhibitors

# Drug_Interactions:
Acarbose	Acarbose may decrease the serum levels of digoin. It is thought that acarbose reduces digoin absorption. Monitor for changes in digoxin serum levels and therapeutic and adverse effects if acarbose is initiated, discontinued or dose changed.
Alprazolam	The benzodiazepine, alprazolam, may increase the effect of digoxin.
Amiodarone	Amiodarone may increase the effect of digoxin.
Bendroflumethiazide	Possible electrolyte variations and arrhythmias
Benzthiazide	Possible electrolyte variations and arrhythmias
Bleomycin	The antineoplasic agent decreases the effect of digoxin
Bosutinib	Bosutinib is a substrate and inhibitor of p-glycoprotein (p-gp) and may increase levels of other p-gp substrates.
Bumetanide	Possible electrolyte variations and arrhythmias
Canagliflozin	When coadministered with 300 mg canagliflozin, the AUC and mean peak drug concentration of digoxin increased. Monitor concomitant therapy closely.
Carmustine	The antineoplasic agent decreases the effect of digoxin
Carvedilol	Carvedilol may increase the serum levels and effect of digoxin.
Chlorothiazide	Possible electrolyte variations and arrhythmias
Chlorthalidone	Possible electrolyte variations and arrhythmias
Cholestyramine	The resin decreases the effect of digoxin
Cinitapride	Cinitapride can alter the absorption of digoxin as it simulates gastric emptying.
Clarithromycin	The macrolide, clarithromycin, may increase the effect of digoxin in 10% of patients.
Colestipol	The resin decreases the effect of digoxin
Cyclophosphamide	The antineoplasic agent decreases the effect of digoxin
Cyclosporine	Cyclosporine may increase the effect of digoxin.
Cyclothiazide	Possible electrolyte variations and arrhythmias
Cytarabine	The antineoplasic agent decreases the effect of digoxin
Dextrothyroxine	The thyroid hormone, dextrothyroxine, decreases the effect of digoxin.
Diazepam	The benzodiazepine, diazepam, may increase the effect of digoxin.
Dihydroquinidine barbiturate	Quinine/quinidine increases the effect of digoxin
Doxorubicin	The antineoplasic agent decreases the effect of digoxin
Dronedarone	Dronedarone inhibits P-glycoprotein transporter thus increasing serum concentrations of digoxin 2.5-fold.
Erythromycin	The macrolide, erythromycin, may increase the effect of digoxin in 10% of patients.
Ethacrynic acid	Possible electrolyte variations and arrhythmias
Etravirine	Digoxin, when administered concomitantly with etravirine, may experience an increase in serum concentration. It is recommended to monitor serum levels of digoxin and titrate dosage to achieve desired therapeutic range. Pre-emptive dose adjustments are not required.
Furosemide	Possible electrolyte variations and arrhythmias
Gatifloxacin	Gatifloxacin increases the effect of digoxin
Ginseng	Changes in digoxin serum levels
Hydrochlorothiazide	Possible electrolyte variations and arrhythmias
Hydroflumethiazide	Possible electrolyte variations and arrhythmias
Hydroxychloroquine	Hydroxychloroquine increases the effect of digoxin
Indapamide	Possible electrolyte variations and arrhythmias
Itraconazole	Itraconazole increases the effect of digoxin
Josamycin	The macrolide, josamycin, may increase the effect of digoxin in 10% of patients.
Levothyroxine	The thyroid hormone, levothyroxine, decreases the effect of digoxin.
Liothyronine	The thyroid hormone, liothyronine, decreases the effect of digoxin.
Liotrix	The thyroid hormone, liotrix, decreases the effect of digoxin.
Methimazole	The antithyroid agent increases the effect of digoxin
Methotrexate	The antineoplasic agent decreases the effect of digoxin
Methyclothiazide	Possible electrolyte variations and arrhythmias
Metolazone	Possible electrolyte variations and arrhythmias
Milnacipran	Use of Savella concomitantly with digoxin may be associated with potentiation of adverse hemodynamic effects. Co-administration of Savella and intravenous digoxin should be avoided.
Mirabegron 	Mirabegron increased Cmax and AUC of digoxin. Initiate therapy with digoxin at lowest possible dose. Monitor concomitant therapy closely.
Penbutolol	Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.
Penciclovir	The multivalent agent decreases the effect of penicillamine
Penicillamine	Penicillamine decreases the effect of digoxin
Polythiazide	Possible electrolyte variations and arrhythmias
Prazosin	Prazosin increases the effect of digoxin
Procarbazine	The antineoplasic agent decreases the effect of digoxin
Propafenone	Propafenone increases the effect of digoxin
Propylthiouracil	The antithyroid agent may increase the effect of digoxin.
Quinethazone	Possible electrolyte variations and arrhythmias
Quinidine	Quinine/quinidine increases the effect of digoxin
Quinidine barbiturate	Quinine/quinidine increases the effect of digoxin
Quinine	Quinine/quinidine increases the effect of digoxin
Rabeprazole	Rabeprazole increases the effect of digoxin
Ranolazine	Ranolazine may increase the serum level of digoxin. Monitor for changes in the serum level and therapeutic and adverse effects of digoxin if ranolazine is initiated, discontinued or dose changed.
Ritonavir	Ritonavir increases levels/effect of digoxin
Spironolactone	Increased digoxin levels and decreased effect in presence of spironolactone
St. John's Wort	St. John's Wort decreases the effect of digoxin
Sulfasalazine	Sulfasalazine may decrease the effect of digoxin.
Telaprevir	Telaprevir is a substrate of p-glycoprotein and thus increases the AUC and Cmax of digoxin. This indicates an increased absorption of digoxin. Lowest dose of digoxin should be used first and levels be closely monitored.
Telithromycin	Telithromycin may increase the plasma concentration of Digoxin. Monitor for changes in Digoxin efficacy/toxicity if Telithromycin is initiated, discontinued or dose changed.
Telmisartan	Telmisartan may increase plasma Digoxin concentrations. Monitor Digoxin levels and adjust dose as required if Telmisartan is initiated, discontinued or dose changed.
Thyroglobulin	The thyroid hormone, thyroglobulin, decreases the effect of digoxin.
Ticlopidine	Ticlopidine may decrease Digoxin levels. Monitor for Digoxin levels with Ticlopidine is initiated, discontinued or dose changed.
Tolbutamide	Tolbutamide increases the effect of digoxin
Tolvaptan	Tolvaptan increases serum digoxin concentrations due to competitive inhibition of P-glycoprotein in the liver, intestine, and kidney. P-glycoprotein facilitates digoxin efflux thus inhibition of this protein will increase incidence of adverse effects.
Trichlormethiazide	Possible electrolyte variations and arrhythmias
Trimetrexate	The absorption of Digoxin, a cardiac glycoside, may be decreased by antineoplastic agents such as Trimetrexate. Liquid forms of Digoxin do not appear to be significantly affected. Monitor Digoxin tablet efficacy if Trimetrexate therapy is initiated, discontinued or if the dose is altered.
Verapamil	Verapamil may increase the serum concentration of Digoxin by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of Digoxin if Verpamail is initiated, discontinued or dose changed.
Vincristine	The antineoplasic agent decreases the effect of digoxin
Voriconazole	Voriconazole may increase the serum concentration of digoxin. Monitor for increased serum concentrations and toxic effects of digoxin if voriconazole is initiated or dose increased.

# Drug_Reference:
15554746	Flanagan RJ, Jones AL: Fab antibody fragments: some applications in clinical toxicology. Drug Saf. 2004;27(14):1115-33.
6665298	Kaplanski J, Weinhouse E, Topaz M, Genchik G: Verapamil and digoxin: interactions in the rat. Res Commun Chem Pathol Pharmacol. 1983 Dec;42(3):377-88.
8094898	Thompson DF, Carter JR: Drug-induced gynecomastia. Pharmacotherapy. 1993 Jan-Feb;13(1):37-45.
857452	Doering W, Konig E, Sturm W: [Digitalis intoxication: specifity and significance of cardiac and extracardiac symptoms. part I: Patients with digitalis-induced arrhythmias (author's transl)] Z Kardiol. 1977 Mar;66(3):121-8.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1.26

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
64.8 mg/L (at 25 °C)

# Food_Interactions:
Avoid avocado.
Avoid bran and high fiber foods within 2 hours of taking this medication.
Avoid excess salt/sodium unless otherwise instructed by your physician.
Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
Avoid salt substitutes containing potassium.
Limit garlic, ginger, gingko, and horse chestnut.

# GenBank_ID:
Not Available

# Generic_Name:
Digoxin

# HET_ID:
Not Available

# Half_Life:
3.5 to 5 days

# InChI_Identifier:
InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1

# InChI_Key:
InChIKey=LTMHDMANZUZIPE-PUGKRICDSA-N

# Indication:
For the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure.

# KEGG_Compound_ID:
C06956

# KEGG_Drug_ID:
D00298

# LIMS_Drug_ID:
390

# Mechanism_Of_Action:
Digoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium. The sodium calcium exchanger (NCX)in turn tries to extrude the sodium and in so doing, pumps in more calcium. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digoxin also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.

# Melting_Point:
249 dec °C

# Molecular_Weight_Avg:
780.9385

# Molecular_Weight_Mono:
780.429606756

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA449319

# Pharmacology:
Digoxin, a cardiac glycoside similar to digitoxin, is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation.

# Predicted_LogP_Hydrophobicity:
1.04

# Predicted_LogS:
-3.8

# Predicted_Water_Solubility:
1.27e-01 g/l

# Primary_Accession_No:
DB00390

# Protein_Binding:
25%

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic/dig.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00098

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Digitalis Glycoside

# Synthesis_Reference:
Not Available

# Toxicity:
Toxicity includes ventricular tachycardia or ventricular fibrillation, or progressive bradyarrhythmias, or heart block. LD<sub>50</sub> = 7.8 mg/kg (orally in mice).

# Update_Date:
2013-02-08 16:19:18 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Digoxin

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_1_ID:
4512

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP11A1

# Phase_1_Metabolizing_Enzyme_2_ID:
6017

# Phase_1_Metabolizing_Enzyme_2_Name:
Cholesterol side-chain cleavage enzyme, mitochondrial

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cholesterol side-chain cleavage enzyme, mitochondrial
MLAKGLPPRSVLVKGCQTFLSAPREGLGRLRVPTGEGAGISTRSPRPFNEIPSPGDNGWL
NLYHFWRETGTHKVHLHHVQNFQKYGPIYREKLGNVESVYVIDPEDVALLFKSEGPNPER
FLIPPWVAYHQYYQRPIGVLLKKSAAWKKDRVALNQEVMAPEATKNFLPLLDAVSRDFVS
VLHRRIKKAGSGNYSGDISDDLFRFAFESITNVIFGERQGMLEEVVNPEAQRFIDAIYQM
FHTSVPMLNLPPDLFRLFRTKTWKDHVAAWDVIFSKADIYTQNFYWELRQKGSVHHDYRG
ILYRLLGDSKMSFEDIKANVTEMLAGGVDTTSMTLQWHLYEMARNLKVQDMLRAEVLAAR
HQAQGDMATMLQLVPLLKASIKETLRLHPISVTLQRYLVNDLVLRDYMIPAKTLVQVAIY
ALGREPTFFFDPENFDPTRWLSKDKNITYFRNLGFGWGVRQCLGRRIAELEMTIFLINML
ENFRVEIQHLSDVGTTFNLILMPEKPISFTFWPFNQEATQQ

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P05108

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11272406	Ravikumar A, Arun P, Devi KV, Augustine J, Kurup PA: Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders. Indian J Exp Biol. 2000 May;38(5):438-46.
11309248	Chen JJ, Wang PS, Chien EJ, Wang SW: Direct inhibitory effect of digitalis on progesterone release from rat granulosa cells. Br J Pharmacol. 2001 Apr;132(8):1761-8.
11324464	Ke YS, Liu ZF, Yang H, Yang T, Huang JS, Rui SB, Cheng GH, Wang YX: Effect of anti-digoxin antiserum on endoxin and membrane ATPase activity in hypoxia-reoxygenation induced myocardial injury. Acta Pharmacol Sin. 2000 Apr;21(4):345-7.
11515751	Kumar AR, Kurup PA: A hypothalamic digoxin mediated model for conscious and subliminal perception. J Neural Transm. 2001;108(7):855-68.
11687608	Aizman O, Uhlen P, Lal M, Brismar H, Aperia A: Ouabain, a steroid hormone that signals with slow calcium oscillations. Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13420-4. Epub 2001 Oct 30.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
ATP1A1

# Drug_Target_1_GenBank_ID_Gene:
D00099

# Drug_Target_1_GenBank_ID_Protein:
219942

# Drug_Target_1_GeneCard_ID:
ATP1A1

# Drug_Target_1_Gene_Name:
ATP1A1

# Drug_Target_1_Gene_Sequence:
>3072 bp
ATGGGGAAGGGGGTTGGACGTGATAAGTATGAGCCTGCAGCTGTTTCAGAACAAGGTGAT
AAAAAGGGCAAAAAGGGCAAAAAAGACAGGGACATGGATGAACTGAAGAAAGAAGTTTCT
ATGGATGATCATAAACTTAGCCTTGATGAACTTCATCGTAAATATGGAACAGACTTGAGC
CGGGGATTAACATCTGCTCGTGCAGCTGAGATCCTGGCGCGAGATGGTCCCAACGCCCTC
ACTCCCCCTCCCACTACTCCTGAATGGATCAAGTTTTGTCGGCAGCTCTTTGGGGGGTTC
TCAATGTTACTGTGGATTGGAGCGATTCTTTGTTTCTTGGCTTATAGCATCCAAGCTGCT
ACAGAAGAGGAACCTCAAAACGATAATCTGTACCTGGGTGTGGTGCTATCAGCCGTTGTA
ATCATAACTGGTTGCTTCTCCTACTATCAAGAAGCTAAAAGTTCAAAGATCATGGAATCC
TTCAAAAACATGGTCCCTCAGCAAGCCCTTGTGATTCGAAATGGTGAGAAAATGAGCATA
AATGCGGAGGAAGTTGTGGTTGGGGATCTGGTGGAAGTAAAAGGAGGAGACCGAATTCCT
GCTGACCTCAGAATCATATCTGCAAATGGCTGCAAGGTGGATAACTCCTCGCTCACTGGT
GAATCAGAACCCCAGACTAGGTCTCCAGATTTCACAAATGAAAACCCCCTGGAGACGAGG
AACATTGCCTTCTTTTCAACAAATTGTGTTGAAGGCACCGCACGTGGTATTGTTGTCTAC
ACTGGGGATCGCACTGTGATGGGAAGAATTGCCACACTTGCTTCTGGGCTGGAAGGAGGC
CAGACCCCCATTGCTGCAGAAATTGAACATTTTATCCACATCATCACGGGTGTGGCTGTG
TTCCTGGGTGTGTCTTTCTTCATCCTTTCTCTCATCCTTGAGTACACCTGGCTTGAGGCT
GTCATCTTCCTCATCGGTATCATCGTAGCCAATGTGCCGGAAGGTTTGCTGGCCACTGTC
ACGGTCTGTCTGACACTTACTGCCAAACGCATGGCAAGGAAAAACTGCTTAGTGAAGAAC
TTAGAAGCTGTGGAGACCTTGGGGTCCACGTCCACCATCTGCTCTGATAAAACTGGAACT
CTGACTCAGAACCGGATGACAGTGGCCCACATGTGGTTTGACAATCAAATCCATGAAGCT
GATACGACAGAGAATCAGAGTGGTGTCTCTTTTGACAAGACTTCAGCTACCTGGCTTGCT
CTGTCCAGAATTGCAGGTCTTTGTAACAGGGCAGTGTTTCAGGCTAACCAGGAAAACCTA
CCTATTCTTAAGCGGGCAGTTGCAGGAGATGCCTCTGAGTCAGCACTCTTAAAGTGCATA
GAGCTGTGCTGTGGTTCCGTGAAGGAGATGAGAGAAAGATACGCCAAAATCGTCGAGATA
CCCTTCAACTCCACCAACAAGTACCAGTTGTCTATTCATAAGAACCCCAACACATCGGAG
CCCCAACACCTGTTGGTGATGAAGGGCGCCCCAGAAAGGATCCTAGACCGTTGCAGCTCT
ATCCTCCTCCACGGCAAGGAGCAGCCCCTGGATGAGGAGCTGAAAGACGCCTTTCAGAAC
GCCTATTTGGAGCTGGGGGGCCTCGGAGAACGAGTCCTAGGTTTCTGCCACCTCTTTCTG
CCAGATGAACAGTTTCCTGAAGGGTTCCAGTTTGACACTGACGATGTGAATTTCCCTATC
GATAATCTGTGCTTTGTTGGGCTCATCTCCATGATTGACCCTCCACGGGCGGCCGTTCCT
GATGCCGTGGGCAAATGTCGAAGTGCTGGAATTAAGGTCATCATGGTCACAGGAGACCAT
CCAATCACAGCTAAAGCTATTGCCAAAGGTGTGGGCATCATCTCAGAAGGCAATGAGACC
GTGGAAGACATTGCTGCCCGCCTCAACATCCCAGTCAGCCAGGTGAACCCCAGGGATGCC
AAGGCCTGCGTAGTACACGGCAGTGATCTAAAGGACATGACCTCCGAGCAGCTGGATGAC
ATTTTGAAGTACCACACTGAGATAGTGTTTGCCAGGACCTCCCCTCAGCAGAAGCTCATC
ATTGTGGAAGGCTGCCAAAGACAGGGTGCTATCGTGGCTGTGACTGGTGACGGTGTGAAT
GACTCTCCAGCTTTGAAGAAAGCAGACATTGGGGTTGCTATGGGGATTGCTGGCTCAGAT
GTGTCCAAGCAAGCTGCTGACATGATTCTTCTGGATGACAACTTTGCCTCAATTGTGACT
GGAGTAGAGGAAGGTCGTCTGATCTTTGATAACTTGAAGAAATCCATTGCTTATACCTTA
ACCAGTAACATTCCCGAGATCACCCCGTTCCTGATATTTATTATTGCAAACATTCCACTA
CCACTGGGGACTGTCACCATCCTCTGCATTGACTTGGGCACTGACATGGTTCCTGCCATC
TCCCTGGCTTATGAGCAGGCTGAGAGTGACATCATGAAGAGACAGCCCAGAAATCCCAAA
ACAGACAAACTTGTGAATGAGCGGCTGATCAGCATGGCCTATGGGCAGATTGGAATGATC
CAGGCCCTGGGAGGCTTCTTTACTTACTTTGTGATTCTGGCTGAGAACGGCTTCCTCCCA
ATTCACCTGTTGGGCCTCCGAGTGGACTGGGATGACCGCTGGATCAACGATGTGGAAGAC
AGCTACGGGCAGCAGTGGACCTATGAGCAGAGGAAAATCGTGGAGTTCACCTGCCACACA
GCCTTCTTCGTCAGTATCGTGGTGGTGCAGTGGGCCGACTTGGTCATCTGTAAGACCAGG
AGGAATTCGGTCTTCCAGCAGGGGATGAAGAACAAGATCTTGATATTTGGCCTCTTTGAA
GAGACAGCCCTGGCTGCTTTCCTTTCCTACTGCCCTGGAATGGGTGTTGCTCTTAGGATG
TATCCCCTCAAACCTACCTGGTGGTTCTGTGCCTTCCCCTACTCTCTTCTCATCTTCGTA
TATGACGAAGTCAGAAAACTCATCATCAGGCGACGCCCTGGCGGCTGGGTGGAGAAGGAA
ACCTACTATTAG

# Drug_Target_1_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_1_General_References:
1970326	Shull MM, Pugh DG, Lingrel JB: The human Na, K-ATPase alpha 1 gene: characterization of the 5'-flanking region and identification of a restriction fragment length polymorphism. Genomics. 1990 Mar;6(3):451-60.
2430951	Kawakami K, Ohta T, Nojima H, Nagano K: Primary structure of the alpha-subunit of human Na,K-ATPase deduced from cDNA sequence. J Biochem (Tokyo). 1986 Aug;100(2):389-97.
2891135	Chehab FF, Kan YW, Law ML, Hartz J, Kao FT, Blostein R: Human placental Na+,K+-ATPase alpha subunit: cDNA cloning, tissue expression, DNA polymorphism, and chromosomal localization. Proc Natl Acad Sci U S A. 1987 Nov;84(22):7901-5.
3035563	Shull MM, Lingrel JB: Multiple genes encode the human Na+,K+-ATPase catalytic subunit. Proc Natl Acad Sci U S A. 1987 Jun;84(12):4039-43.
3036582	Sverdlov ED, Monastyrskaya GS, Broude NE, Ushkaryov YuA, Allikmets RL, Melkov AM, Smirnov YuV, Malyshev IV, Dulobova IE, Petrukhin KE, et al.: The family of human Na+,K+-ATPase genes. No less than five genes and/or pseudogenes related to the alpha-subunit. FEBS Lett. 1987 Jun 15;217(2):275-8.
7536695	Ruiz A, Bhat SP, Bok D: Characterization and quantification of full-length and truncated Na,K-ATPase alpha 1 and beta 1 RNA transcripts expressed in human retinal pigment epithelium. Gene. 1995 Apr 3;155(2):179-84.

# Drug_Target_1_HGNC_ID:
HGNC:799

# Drug_Target_1_HPRD_ID:
01662

# Drug_Target_1_ID:
806

# Drug_Target_1_Locus:
1p21

# Drug_Target_1_Molecular_Weight:
112897

# Drug_Target_1_Name:
Sodium/potassium-transporting ATPase alpha-1 chain

# Drug_Target_1_Number_of_Residues:
1023

# Drug_Target_1_PDB_ID:
1MO8

# Drug_Target_1_Pathway:
Amiloride Pathway	SMP00133
Benazepril Pathway	SMP00145
Bendroflumethiazide Pathway	SMP00090
Benzocaine Pathway	SMP00392
Bumetanide Pathway	SMP00088
Bupivacaine Pathway	SMP00393
Captopril Pathway	SMP00146
Chloroprocaine Pathway	SMP00394
Chlorothiazide Pathway	SMP00078
Chlorthalidone Pathway	SMP00122
Cilazapril Pathway	SMP00147
Cocaine Pathway	SMP00395
Cyclothiazide Pathway	SMP00103
Dibucaine Pathway	SMP00396
Diltiazem Pathway	SMP00359
Disopyramide Pathway	SMP00325
Enalapril Pathway	SMP00148
Eplerenone Pathway	SMP00135
Ethacrynic Acid pathway	SMP00097
Flecainide Pathway	SMP00331
Fosinopril Pathway	SMP00149
Fosphenytoin (Antiarrhythmic) Pathway	SMP00326
Furosemide Pathway	SMP00115
Hydrochlorothiazide Pathway	SMP00100
Hydroflumethiazide Pathway	SMP00108
Ibutilide Pathway	SMP00332
Indapamide Pathway	SMP00110
Levobupivacaine Pathway	SMP00397
Lidocaine (Antiarrhythmic) Pathway	SMP00328
Lidocaine (Local Anaesthetic) Pathway	SMP00398
Lisinopril Pathway	SMP00150
Mepivacaine Pathway	SMP00399
Methyclothiazide Pathway	SMP00081
Metolazone Pathway	SMP00105
Mexiletine Pathway	SMP00329
Moexipril Pathway	SMP00151
Oxybuprocaine Pathway	SMP00400
Perindopril Pathway	SMP00152
Phenytoin (Antiarrhythmic) Pathway	SMP00327
Polythiazide Pathway	SMP00080
Prilocaine Pathway	SMP00401
Procainamide (Antiarrhythmic) Pathway	SMP00324
Procaine Pathway	SMP00402
Proparacaine Pathway	SMP00403
Quinapril Pathway	SMP00153
Quinethazone Pathway	SMP00091
Quinidine Pathway	SMP00323
Ramipril Pathway	SMP00154
Rescinnamine Pathway	SMP00155
Ropivacaine Pathway	SMP00404
Spirapril Pathway	SMP00156
Spironolactone Pathway	SMP00134
Tocainide Pathway	SMP00330
Torsemide Pathway	SMP00118
Trandolapril Pathway	SMP00157
Triamterene Pathway	SMP00132
Trichlormethiazide Pathway	SMP00121
Verapamil Pathway	SMP00375

# Drug_Target_1_Pfam_Domain_Function:
PF00122	E1-E2_ATPase
PF00689	Cation_ATPase_C
PF00690	Cation_ATPase_N
PF00702	Hydrolase

# Drug_Target_1_Protein_Sequence:
>Sodium/potassium-transporting ATPase alpha-1 chain precursor
MGKGVGRDKYEPAAVSEQGDKKGKKGKKDRDMDELKKEVSMDDHKLSLDELHRKYGTDLS
RGLTSARAAEILARDGPNALTPPPTTPEWIKFCRQLFGGFSMLLWIGAILCFLAYSIQAA
TEEEPQNDNLYLGVVLSAVVIITGCFSYYQEAKSSKIMESFKNMVPQQALVIRNGEKMSI
NAEEVVVGDLVEVKGGDRIPADLRIISANGCKVDNSSLTGESEPQTRSPDFTNENPLETR
NIAFFSTNCVEGTARGIVVYTGDRTVMGRIATLASGLEGGQTPIAAEIEHFIHIITGVAV
FLGVSFFILSLILEYTWLEAVIFLIGIIVANVPEGLLATVTVCLTLTAKRMARKNCLVKN
LEAVETLGSTSTICSDKTGTLTQNRMTVAHMWFDNQIHEADTTENQSGVSFDKTSATWLA
LSRIAGLCNRAVFQANQENLPILKRAVAGDASESALLKCIELCCGSVKEMRERYAKIVEI
PFNSTNKYQLSIHKNPNTSEPQHLLVMKGAPERILDRCSSILLHGKEQPLDEELKDAFQN
AYLELGGLGERVLGFCHLFLPDEQFPEGFQFDTDDVNFPIDNLCFVGLISMIDPPRAAVP
DAVGKCRSAGIKVIMVTGDHPITAKAIAKGVGIISEGNETVEDIAARLNIPVSQVNPRDA
KACVVHGSDLKDMTSEQLDDILKYHTEIVFARTSPQQKLIIVEGCQRQGAIVAVTGDGVN
DSPALKKADIGVAMGIAGSDVSKQAADMILLDDNFASIVTGVEEGRLIFDNLKKSIAYTL
TSNIPEITPFLIFIIANIPLPLGTVTILCIDLGTDMVPAISLAYEQAESDIMKRQPRNPK
TDKLVNERLISMAYGQIGMIQALGGFFTYFVILAENGFLPIHLLGLRVDWDDRWINDVED
SYGQQWTYEQRKIVEFTCHTAFFVSIVVVQWADLVICKTRRNSVFQQGMKNKILIFGLFE
ETALAAFLSYCPGMGVALRMYPLKPTWWFCAFPYSLLIFVYDEVRKLIIRRRPGGWVEKE
TYY

# Drug_Target_1_Reaction:
ATP + H2O + Na+in + K+out = ADP + phosphate + Na+out + K+in

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients

# Drug_Target_1_SwissProt_ID:
P05023

# Drug_Target_1_SwissProt_Name:
AT1A1_HUMAN

# Drug_Target_1_Synonyms:
EC 3.6.3.9
Na(+)/K(+) ATPase alpha-1 subunit
Sodium pump subunit alpha 1
Sodium/potassium-transporting ATPase alpha-1 chain precursor

# Drug_Target_1_Theoretical_pI:
5.15

# Drug_Target_1_Transmembrane_Regions:
88-108
132-152
289-308
321-338
773-792
803-823
844-866
919-938
952-970
986-1006

#END_DRUGCARD DB00390
